



## Marco Siano

### Kontakt

Marco Siano

T +41 71 494 3539

### Bereiche

Medizinische Onkologie und Hämatologie

## Publikationen (55)

Schuler A, Huser J, Schmid S, Schär S, Scherz A, Gautschi O, Mauti L, von Briel T, Waibel C, Wannesson L, Pankovics J, Mark M, Rothschild S, Addeo A, Janthur W, Siano M, Boos L, Britschgi C, Früh M. Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study. *Lung Cancer* 2023; 187:107427.

Bickel A, Diem S, Flatz L, Stinn B, Siano M. First-line treatment of NRAS-mutated metastatic melanoma with a MEK inhibitor. *J Cancer Res Ther* 2021; 17:276-278.

Müller J, Früh M, Siano M. Radiation dosimetry of 18F-AzaFol: A first inhuman use of a folate receptor PET tracer. *EJNMMI Research* 2020; 10

Gnesin S, Prior J, Treyer V, Kaufmann P, Ametamey S, Schibli R, Müller C, Choschzick M, Früh M, Siano M, Meisel A, Burger I, Müller J, Schaefer N. Radiation dosimetry of F-AzaFol: A first in-human use of a folate receptor PET tracer. *EJNMMI Res* 2020; 10:32.

Brogliè M, Negri S, Rothschild S, Giger R, Beffa L, Ballerini G, Huber G, Zwahlen D, Simon C, Putora P, Siano M, Henke G, Dulguerov P, Elicin O. A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 4 (Biomarkers). *Front Oncol* 2019; 9:1128.

Siano M, Negri S, Rothschild S, Giger R, Beffa L, Ballerini G, Huber G, Zwahlen D, Simon C, Putora P, Henke G, Brogliè M, Dulguerov P, Elicin O. A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 3 (Medical Oncology). *Front Oncol* 2019; 9:1127.

Elicin O, Dulguerov P, Negri S, Rothschild S, Giger R, Beffa L, Ballerini G, Huber G, Zwahlen D, Simon C, Brogliè M, Siano M, Putora P, Henke G. A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 2 (Radiation Oncology). *Front Oncol* 2019; 9:1126.

den Hollander J, Negri S, Rothschild S, Giger R, Beffa L, Ballerini G, Huber G, Zwahlen D, Simon C, Putora P, Siano M, Henke G, Brogliè M, Elicin O. A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 1 (Head and Neck Surgery). *Front Oncol* 2019; 9:1125.

Fässler M, Jörger M, Recher M, Risch L, Gusewell S, Risch M, Speiser D, Ludewig B, Levesque M, Dummer R, Siano M, Krolík M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Gil Cruz C, Pérez Shibayama C, Flatz L. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. *J Immunother Cancer* 2019; 7:50.

Siano M, Espeli V, Jörger M. Time to systemic treatment and prognosis in patients with recurrent and metastatic head and neck squamous cell cancer. *Tumori* 2018;300891618811276.

Diem S, Früh M, Gusewell S, Schmid S, Ackermann C, Roux G, Berner F, Niederer R, Siano M, Ali O, Fässler M, Flatz L. Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment. *Cancer Manag Res* 2018; 10:5537-5544.

Hirschmann A, Lupatsch J, Schwenkglenks M, Panje C, Matter-Walstra K, Espeli V, Dedes K, Siano M, Swiss Group of Clinical Cancer Research (SAKK). Cost-effectiveness of nivolumab in the treatment of head and neck cancer. *Oral Oncol* 2018; 87:104-110.

Espele V, Vergotte S, Dietrich P, Pichard C, Siano M. Prolonged Versus Short-Duration Use of Nasogastric Tubes in Patients with Head and Neck Cancer During Radiotherapy Alone or Combined Chemoradiotherapy. *Nutr Cancer* 2018;1-6.

Panje C, Lupatsch J, Plasswilm L, Aebersold D, Siano M, Gautschi O, Schwenkglenks M, Matter-Walstra K, Dedes K, Swiss Group for Clinical Cancer Research (SAKK). A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC). *Radiother Oncol* 2018; 129:257-263.

Siano M, Jarisch N, Jörger M, Espele V. Percutaneous Endoscopic Gastrostomy Tube Is a Negative Prognostic Factor for Recurrent/Metastatic Head and Neck Cancer. *Anticancer Res* 2018; 38:3725-3729.

Siano M, Espele V, Mach N, Bossi P, Licitra L, Ghielmini M, Frattini M, Canevari S, De Cecco L. Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial. *Oral Oncol* 2018; 82:144-151.

Fischer S, Ali O, Jochum W, Kluckert J, Flatz L, Siano M. Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma. *Oncol Res Treat* 2018; 41:391-394.

Balmelli C, Stenner F, Pless M, Weidner S, Zimmermann S, Gütthner C, Cristina V, Cathomas R, Feuerlein K, Siano M, Railic N, Rothschild S. Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program. *J Cancer* 2018; 9:250-255.

Bossi P, Licitra L, Canevari S, Locati L, Pilotti S, Perrone F, Marchesi E, Paoli A, Tonella L, Giannoccaro M, Sponghini A, Cossu Rocca M, Bergamini C, Siano M, De Cecco L. Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?. *Dis Markers* 2017; 2017:6870614.

Siano M, Frattini M, Ghielmini M, Corradino I, Freguia S, Früh M, Mach N, Martin V, Molinari F, Espele V. Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer. *Oncologist* 2017

Siano M, Licitra L, Locati L, Miceli R, Granata R, Bergamini C, Alfieri S, Cau M, Resteghini C, Infante G, Bossi P. Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy. *Oral Oncol* 2017; 69:33-37.

Siano M (2016). Presence of percutaneous endoscopic gastrostomy tube (PEG) is an independent negative prognostic factor in recurrent/metastatic head and neck squamous cell cancer (r/mHNSCC) patients.

Siano M (2016). Baseline neutrophil-to-lymphocyte ratio is associated with outcome in recurrent/metastatic head and neck squamous cell cancer patients treated with platinum and cetuximab in first line setting.

Bossi P, Canevari S, Licitra L, Locati L, Pilotti S, Perrone F, Cortelazzi B, Marchesi E, Giannoccaro M, Favales F, Sponghini A, Cossu Rocca M, Siano M, Bergamini C, De Cecco L. Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab. *Clin Cancer Res* 2016; 22:3961-70.

Dummer R, Guckenberger M, Najafi Y, von Moos R, Mihic-Probst D, Michielin O, Braun R, Lindenblatt N, Hunger R, Siano M, Arnold A. The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma. *Swiss Med Wkly* 2016; 146:w14279.

Diem S, Goldinger S, Urner-Bloch U, Siano M, Dummer R, Speiser D, Maillard S, Rüesch R, Keller F, Flatz L. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?. J Immunother 2016; 39:379-382.

Zürrer-Härdi U, Siano M, Broglie Däppen M. Knochenmarksversagen bei Tumordinfiltration bei einem Patienten mit Ästhesioneuroblastom, Mantelzell-Non-Hodgkin-Lymphom und Rektumkarzinom. Schweiz. Krebsbulletin 2015; 1:98-101.

Siano M (2015). Thyroid cancers: which molecular markers are relevant?.

Siano M (2015). Survival of recurrent/metastatic head and neck squamous cell cancer (r/mHNSCC) patients (pts) treated in 1st or 2nd line with an anti-EGFR-antibody (EAB). Präsentiert bei: DGHO 2015, Basel

Siano M (2015). Systemic treatment pattern in a large cohort of recurrent/metastatic head and neck squamous cell cancer (r/m HNSCC) patients (pts) treated at a tertiary cancer centre. Präsentiert bei: DGHO 2015, -

Cau M, Alfieri S, Siano M (2015). Site of metastatic disease influences adenoid cystic cancer (ACC) patients' outcome.

Siano M (2015). Phase II explorative trial to prospectively investigate predictive molecular biomarkers for efficacy of panitumumab (P) in platinum-pretreated head and neck squamous cell cancer (HNSCC).

Siano M, Resteghini c, Licitra L, Bossi P (2015). Outcome of systemic treatments after first line platinum and cetuximab treatment in patients with recurrent/metastatic (RM) head and neck squamous cell cancer (HNSCC): a retrospective analysis.

Siano M (2015). Prospective multicenter phase II study of the anti-EGFR (epidermal growth factor receptor) antibody panitumumab (P) in patients with platinum pre-treated, advanced head and neck squamous cell cancer (HNSCC).

Feilchenfeldt J, Jochum W, Shoji H, Kushima R, Wagner D, Shimada Y, Cats A, Knuth A, Moch H, Aebi S, Diebold J, Khanfir K, Varga Z, Siano M, Grabsch H, Held U, Schuknecht B, Trip A, Hamaguchi T, Gut P, Balague O, Hofer S. Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2). Br J Cancer 2015; 113:716-21.

Siano M (2015). Time of referral of patients (pts) with recurrent/metastatic (r/m) head and neck squamous cell cancer (HNSCC) to medical oncology and survival.

AC V, Siano M, Broglie Däppen M, Toepfer M, Stöckli S. Das Adenoidzystische-Karzinom. info@onkologie.ch 2015; 1:10-12.

Zürrer-Härdi U, Siano M, Blum D. Antiemese und Tumormedikation. info@onkologie.ch 2015; 1:20-26.

Siano M. Schilddrüsenkarzinom – News-ASCO und Integration in den klinischen Alltag. Leading Opinions Hämatologie / Onkologie 2015; 4

Litschel R, Siano M, Tasman A, Cogliatti S. Nasolacrimal duct obstruction caused by lymphoproliferative infiltration in the course of chronic lymphocytic leukemia. Allergy Rhinol (Providence) 2015; 6:191-4.

Schmid S, Siano M, Joerger M, Rodriguez R, Müller J, Früh M. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma. *Lung Cancer* 2014; 87:85-7.

Feilchenfeldt J, Varga Z, Schuknecht B, Siano M, Hofer S (2014). Gastric cancer and CNS involvement registry.

Böhler N, Siano M, Anliker M. Phototoxische Medikamente: Wichtigkeit der Patienteninstruktion. *Swiss Medical Forum* 2014; 14:132-134.

Siano M. Medulläres Schilddrüsenkarzinom – Eine eigene Entität. *info@onkologie* 2013 2013; 3:37-39.

Siano M. CECOG experts' recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer. *memo* 2013; 6:75-82.

Hochstrasser A, Hundsberger T, Siano M. Secondary spinal anaplastic ependymoma ten years after treatment of Hodgkin's disease. *Schweiz. Krebsbulletin* 2013; 2:175-178.

Bossi P, Siano M. Identification of a gene expression profile associated with progression-free survival (PFS) in relapsed or metastatic (RM) head and neck squamous cell cancer (HNSCC) patients (pts) treated with first-line cetuximab and platinum therapy. *JCO Journal of Clinical Oncology* 2013; 31

Uster A, Ruefenacht U, Ruehlin M, Pless M, Siano M, Haefner M, Imoberdorf R, Ballmer P. Influence of a nutritional intervention on dietary intake and quality of life in cancer patients: a randomized controlled trial. *Nutrition* 2013; 29:1342-9.

Siano M. Systemic therapy of neuroendocrine tumors of the lung – Review. *Lung Cancer Management* 2012; 1:1-8.

Früh M, Pless M, Fustier P, Küttel E, Simcock M, Rauch D, Krasniqi F, Erdmann A, Mamot C, Zippelius A, Tscherry G, Siano M, Cathomas R, Swiss Group for Clinical Cancer Research. Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08). *Clin Lung Cancer* 2012; 14:34-9.

Siano M. Die Therapie beim NSCLC in kurativer Absicht – Aktuelle Modalitäten in allen Krankheitsstadien: eine Übersicht. *Schweizerische Zeitschrift für Onkologie* 2012:17-22.

Uster A, Rühlin M, Rüfenacht U, Pless M, Siano M, Imoberdorf R, Ballmer p. Individuelle Ernährungsberatung bewirkt eine signifikante Steigerung der Energie- und Eiweisszufuhr bei unterernährten, ambulanten Krebspatienten: Eine kontrollierte, randomisierte Studie. *Ernährung* 2012

Siano M, Gallino A, Sessa C, Mora O, Leoncini L, Oberson M, Rodriguez-Abreu D, Zucca E, Negretti L, Lerch E, Ghielmini M. A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2008; 14:7935-9.

Siano M. Wirksamkeit von Alemtuzumab und Gemcitabine in einer Patientin mit enteropathischem T-Zell Lymphom – Der seltene Fall. *Schweizer Krebsbulletin* 2007; 27

Siano M. Vaginal sacrospinous ligament fixation – a minimal invasive procedure?. *Dissertation* 2005

## Projekte (9)

**A phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum doublet) and crizotinib**

*Klinische Forschung - 04.12.2013 - 04.12.2013*

*Automatisch geschlossen*

**ETOP 2-11 (BELIEF) An open-label phase II trial of erlotinib and bevacizumab in patients with advanced non-small cell lung cancer and activating EGFR mutations**

*Klinische Forschung - 17.09.2012 - 27.09.2022*

*Automatisch geschlossen*

**Cytochrom p450 3A4 and 1A2 phenotyping for the individualization of treatment with sunitinib or erlotinib in cancer patients**

*Klinische Forschung - 15.01.2012 - 31.07.2015*

*Automatisch geschlossen*

**A randomized double blind phase 3 efficacy and safety study of PF-00299804 versus erlotinib for the treatment of advanced non-small cell lung cancer following progression after, or intolerance to, at least one prior chemotherapy**

*Klinische Forschung - 13.01.2012 - 31.12.2013*

*Automatisch geschlossen*

**Phase II study to investigate the efficacy of panitumumab in platinum-resistant advanced head and neck squamous cancer**

*Klinische Forschung - 03.09.2011 - 31.10.2012*

*Automatisch geschlossen*

**An open-label, randomized, parallel group study of patients treated with Paclitaxel with standard dosing versus pharmacokinetic guided dose adjustment in patients with advanced NSCLC**

*Klinische Forschung - 10.08.2011 - 30.06.2012*

*Abgeschlossen*

**Bevacizumab, pemetrexed and cisplatin, or erlotinib and bevacizumab for advanced non-squamous NSCLC stratified by EGFR mutation status. A multicenter phase II trial including biopsy at progression (BIO-PRO trial)**

*Klinische Forschung - 05.10.2010 - 31.12.2014*

*Automatisch geschlossen*

**Preoperative chemotherapy and radiotherapy concomitant to Cetuximab in non-small cell lung cancer (NSCLC) patients with IIIB disease. A multicenter phase II trial**

*Klinische Forschung - 16.06.2010 - 30.04.2011*

*Automatisch geschlossen*

**Carboplatin and Paclitaxel plus ASA404 as first line chemotherapy for extensive-stage small-cell lung cancer (ES-SCLC): A phase II trial**

*Klinische Forschung - 08.02.2010 - 01.10.2011*

*Automatisch geschlossen*

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch